Table.

Writing Group Disclosures

Writing Group MemberEmploymentResearch GrantOther Research SupportSpeakers' Bureau/HonorariaExpert WitnessOwnership InterestConsultant/Advisory BoardOther
Philip B. GorelickUniversity of IllinoisNoneNoneNoneNoneNone NoneNone
Angelo ScuteriINRCA–IRCCS (Rome, Italy)NoneNoneNoneNoneNoneNoneNone
Donna K. ArnettUniversity of Alabama at BirminghamNoneNoneNoneNoneNoneNoneNone
David A. BennettRush University Medical CenterNoneNoneNoneNoneNoneNoneNone
Sandra E. BlackUniversity of TorontoNIHNoneEisai*; Janssen-Ortho*; Lundbeck*; Novartis Pharmaceuticals*; Pfizer*NoneNoneBristol-Myers Squibb*; Elan Pharmaceuticals*; GlaxoSmithKline*; Janssen-Ortho*; Lundbeck*; Novartis Pharmaceuticals*; Pfizer Wyeth Pharmaceuticals*None
Helena C. ChuiUniversity of Southern CaliforniaNoneNoneNoneNoneNoneNoneNone
Charles DeCarliUniversity of California, DavisMerck; NIHNoneNoneNoneNoneBristol-Myers Squibb*; Merck*; Theravance*None
Steven M. GreenbergMassachusetts General HospitalNIH; NINDSNoneNoneNoneNoneBristol-Myers Squibb*; Hoffmann-La Roche*; Janssen Alzheimer Immunotherapy*; Medtronic*None
Randall T. HigashidaUniversity of California at San FranciscoNoneNoneNoneNoneNoneNoneNone
Costantino IadecolaWeill Cornell Medical CollegeNIH/NINDSNoneNoneNoneNoneNoneNone
Lenore J. LaunerNational Institutes of Health–National Institute on AgingNIHNoneNoneNoneNoneNoneNone
Stephane LaurentUniversity of Paris DescartesDaiichi-Sankyo*; Novartis*; Servier*NoneAstraZeneca*; Boehringer Ingelheim*; Chiesi*; Daiichi-Sankyo*; Negma*; Novartis*; Pfizer*; Recordati*; Servier*NoneNoneNoneNone
Ruth LindquistUniversity of Minnesota and Minneapolis Heart InstituteNoneNoneNoneNoneNoneNoneNone
Oscar L. LopezUniversity of PittsburghNIANoneNoneNoneNoneBristol-Myers Squibb*; Pfizer*None
Peter M. NilssonLund University of SwedenNoneNoneNoneNoneNoneNoneNone
David NyenhuisUniversity of IllinoisNIH/NINDSNoneNoneNoneNoneNoneNone
Ronald C. PetersenMayo ClinicNoneNoneNoneNoneNoneElan Pharma*; GE Healthcare*; Wyeth Pharmaceuticals*None
Gustavo C. RomanMethodist Neurological Institute in Houston, TXNoneNoneFerrer*NoneNoneFerrer*None
Julie A. SchneiderRush Alzheimer's Disease Center–Rush UniversityNIHNoneNoneNoneNoneAvid Radiopharmaceuticals*; GE Healthcare*None
Frank W. SellkeLifespan, Brown Medical SchoolCapstone*; Ikaria*; NIHNoneNonePfizerNoneCubist DSMB*; Edwards Lifesciences DSMB*; Novo Nordisk DSMB*None
Sudha SeshadriBoston University School of MedicineNIANoneNoneNoneNoneNoneNone
Christophe TzourioINSERM–Paris, France (National Institute for Health and Medical Research)French Alzheimer PlanNoneNoneNoneNoneNoneNone
  • This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

  • * Modest.

  • Significant.